Calidi Biotherapeutics Inc. (NYSE American: CLDI) has appointed Eric Poma, PhD, as its new chief executive officer and a member of the board of directors. This strategic appointment aims to leverage Dr. Poma's extensive experience in oncology, fundraising, and strategic partnerships to propel the company's innovative therapies through clinical development and toward commercialization. Dr. Poma's background in the biotech industry and his comprehensive understanding of the oncology landscape are expected to be invaluable as Calidi Biotherapeutics continues to pioneer stem cell-based platforms for cancer treatment.
The company's proprietary technology aims to enhance the immune system's ability to fight cancer, utilizing allogeneic stem cells to deliver oncolytic viruses directly to tumors, including high-grade gliomas and solid tumors. This leadership transition comes at a critical juncture for Calidi Biotherapeutics, which is advancing clinical-stage off-the-shelf, universal cell-based delivery platforms and preclinical off-the-shelf enveloped virotherapies. The company is at the forefront of developing treatments that could potentially prevent metastatic disease, with its focus on improving efficacy and patient safety through a dual approach to treating or preventing metastatic cancer.
The appointment of Dr. Poma underscores the company's commitment to advancing these groundbreaking therapies to benefit patients worldwide. Calidi Biotherapeutics' innovative approach represents a promising avenue in the fight against one of the world's most challenging diseases, highlighting the potential impact of its work on the oncology field and beyond. The company's developments can be followed through its corporate communications at https://www.calidibio.com.
